OCWP
FATE icon

Owl Creek Wealth Partners’s Fate Therapeutics FATE Stock Holding History

Owl Creek Wealth Partners’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.3K Hold
4,190
– – ﹤0.01% 807
2026
Q1 		$5.03K Buy
+4,190
New +$5.1K ﹤0.01% 971

Other funds holding FATE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Owl Creek Wealth Partners's FATE Position: Q2 2026 in Review

Owl Creek Wealth Partners held its Fate Therapeutics (FATE) position steady in Q2 2026 at 4,190 shares worth $11.3K. The position accounts for ﹤0.01% of the portfolio, ranked #807.

Owl Creek Wealth Partners first reported a position in FATE in Q1 2026 and has held it in 2 quarters since. 141 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Owl Creek Wealth Partners held 4,190 shares of Fate Therapeutics worth $11.3K as of Q2 2026.
  • Owl Creek Wealth Partners left its Fate Therapeutics share count unchanged in Q2 2026.
  • Fate Therapeutics made up ﹤0.01% of Owl Creek Wealth Partners's portfolio in Q2 2026, its #807 holding.
  • Owl Creek Wealth Partners first reported a position in Fate Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 141 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Owl Creek Wealth Partners's 13F filing for Q2 2026, filed 20 Jul 2026.